Feb 2, 2023
Viral samples collected from dozens of covid patients suggest that Merck & Co.'s new anti-viral covid drug Lagevrio (molnupiravir) is triggering the formation of new "strains" of the disease. A preprint study compiled by researchers from the U.S.-based Francis Crick Institute and Imperial College London explains that the drug-linked mutations of the so-called "virus" are not necessarily more immune-evasive or lethal, but they are occurring. The fact that mutations are happening at all, rather than the "miracle cure" that Merck claimed would happen, is concerning - especially as the drug gains traction in communist China and elsewhere. The way Lagevrio works is it creates mutations in the covid genome that supposedly prevent the virus from replicating inside the body, thus reducing the chance of severe illness. By nature of how the drug works, though, the mutations that inevitably result could be problematic. "There's always bee